Tapinarof(GSK2894512乳膏)治疗斑块状银屑病的2期随机剂量探索研究
这项双盲、赋形剂对照、随机、6臂试验在体表面积受累≥1%且≤15%、基线医师整体评估(PGA)评分≥2的成人银屑病患者中评估两种浓度和两种用药频率的tapinarof乳膏。第12周时tapinarof各组PGA 0或1且较基线改善2级的治疗成功率显著高于赋形剂组,且治疗后维持4周;tapinarof组治疗中出现的不良事件更常见,多为轻至中度。结论认为tapinarof乳膏对成人银屑病患者有效且耐受性良好。
要点
- 第12周PGA 0或1且改善2级的成功率:tapinarof 1%每日2次65%、1%每日1次56%、0.5%每日2次46%、0.5%每日1次36%,赋形剂每日2次11%、每日1次5%。
- 治疗成功率在治疗后维持4周。
- tapinarof组治疗中出现的不良事件85/152(56%)多于赋形剂组19/75(25%),多为轻至中度。
核心结论
- tapinarof乳膏对成人银屑病患者有效且耐受性良好。
研究设计与样本
- 双盲、赋形剂对照、随机、6臂(1:1:1:1:1:1)试验,纳入体表面积受累≥1%且≤15%、基线PGA评分≥2的成人银屑病患者。
主要发现
- 第12周PGA 0或1且较基线改善2级的治疗成功率在tapinarof组为65%(1%每日2次)、56%(1%每日1次)、46%(0.5%每日2次)、36%(0.5%每日1次),均显著高于赋形剂组11%(每日2次)和5%(每日1次)(0.05显著性水平)。
- 治疗成功率在治疗后维持4周。
- 治疗中出现的不良事件在tapinarof组为85/152(56%),多于赋形剂组19/75(25%),强度多为轻至中度。
- 除0.5%每日1次组外,所有tapinarof组均报告了严重治疗中出现的不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要大型确证性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a significant need for novel, safe, and efficacious topical treatments for psoriasis. OBJECTIVE: We assessed the safety and efficacy of tapinarof in a new cream formulation at 2 concentrations and with 2 application frequencies in adults with psoriasis. METHODS: Double-blind, vehicle-controlled, randomized, 6-arm trial (1:1:1:1:1:1) in adults, with psoriasis with body surface involvement ≥1% and ≤15% and Physician Global Assessment (PGA) score ≥2 at baseline. Primary endpoint included PGA of 0 or 1 at week 12 and a 2-grade improvement from baseline. Additional analyses included assessment of ≥75% improvement of Psoriasis Area and Severity Index and mean percent change in Psoriasis Area and Severity Index and body surface area involvement. RESULTS: Treatment success defined by PGA 0 or 1 and a 2-grade improvement at week 12 was statistically significantly higher (at a .05 significance level) in the tapinarof groups (65% [1% twice daily], 56% [1% once daily], 46% [0.5% twice daily], and 36% [0.5% once daily]) than in the vehicle groups (11% [twice daily] and 5% [once daily]) and was maintained for 4 weeks posttreatment. Treatment-emergent adverse events were more frequent in patients treated with tapinarof (85/152, 56%) than vehicle (19/75, 25%) and mild-to-moderate in intensity. Severe treatment-emergent adverse events were reported in all tapinarof groups except the 0.5% once daily group. LIMITATIONS: Large confirmation trials are needed. CONCLUSIONS: Tapinarof cream is efficacious and well tolerated in adult patients with psoriasis.
引用
- Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2018. PMID: 30612986. doi:10.1016/j.jaad.2018.10.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。